1. Academic Validation
  2. Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae

Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae

  • Molecules. 2016 Nov 17;21(11):1562. doi: 10.3390/molecules21111562.
Hee-Soo Park 1 Sang-Hun Oh 2 Hye-Shin Kim 3 Dong-Rack Choi 4 Jin-Hwan Kwak 5
Affiliations

Affiliations

  • 1 School of Food Science and Biotechnology, Kyungpook National University, Daegu 41566, Korea. phsoo97@knu.ac.kr.
  • 2 School of Life Science, Handong Global University, 558 Handong-ro, Buk-gu, Pohang 37554, Korea. osh8755@naver.com.
  • 3 School of Life Science, Handong Global University, 558 Handong-ro, Buk-gu, Pohang 37554, Korea. momobile217@gmail.com.
  • 4 Dong Wha Pharm., Ind. Co. Ltd., Anyang 31041, Korea. dongrack.choi@dong-wha.co.kr.
  • 5 School of Life Science, Handong Global University, 558 Handong-ro, Buk-gu, Pohang 37554, Korea. jhkwak@handong.edu.
Abstract

Zabofloxacin is a novel fluoroquinolone agent that has potent activity against gram-positive pathogens. In this study, we confirmed that zabofloxacin showed the most potent in vitro and in vivo activities against drug-resistant Streptococcus pneumoniae. Among the fluoroquinolone compounds, zabofloxacin showed the most potent in vitro activity against clinical isolates of penicillin-sensitive S. pneumoniae (minimum inhibitory concentration, MIC90: 0.03 mg/L) and penicillin-resistant S. pneumoniae (MIC90: 0.03 mg/L). Against quinolone-resistant S. pneumoniae, zabofloxacin (MIC90: 1 mg/L) was more active than ciprofloxacin, sparfloxacin, and moxifloxacin; however, its activity was the same as that of gemifloxacin. The in vivo activity of zabofloxacin was most potent among the Quinolone compounds tested against the systemic Infection and respiratory tract Infection models in mice.

Keywords

Streptococcus pneumoniae; in vivo; minimum inhibitory concentration; zabofloxacin.

Figures
Products